ERBB2 and breast carcinoma: Currently, chemotherapy is commonly adopted in HER2-negative breast cancer management, of which taxane-anthracycline combination regimens have been regarded as typical neoadjuvant chemotherapeutic strategies (Hanusch et al., 2015).